The Zeglis Lab is focused on the synthesis, development, and validation of diagnostic, theranostic, and therapeutic agents for disease, particularly cancer. He is particularly interested in working at the intersection of molecular design, bioorthogonal chemistry, and radiochemistry. His lab is currently working toward the creation of novel strategies for the site-specific labeling of immunoglobulins as well as the development of pretargeted methodologies for PET imaging and radioimmunotherapy.